Cargando…

Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer

BACKGROUND: To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV(max)) at 60 min (SUV(max)1) and SUV(max) at 120 min (SUV(max)2) (ΔSUV(max)%) using dual time point (18)F-fluorodeoxyglucose emission tomography/computed...

Descripción completa

Detalles Bibliográficos
Autores principales: YAMAGISHI, Yoji, KOIWAI, Tomomi, YAMASAKI, Tamio, EINAMA, Takahiro, FUKUMURA, Makiko, HIRATSUKA, Miyuki, KONO, Takako, HAYASHI, Katsumi, ISHIDA, Jiro, UENO, Hideki, TSUDA, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882358/
https://www.ncbi.nlm.nih.gov/pubmed/31775675
http://dx.doi.org/10.1186/s12885-019-6315-8
_version_ 1783474142949933056
author YAMAGISHI, Yoji
KOIWAI, Tomomi
YAMASAKI, Tamio
EINAMA, Takahiro
FUKUMURA, Makiko
HIRATSUKA, Miyuki
KONO, Takako
HAYASHI, Katsumi
ISHIDA, Jiro
UENO, Hideki
TSUDA, Hitoshi
author_facet YAMAGISHI, Yoji
KOIWAI, Tomomi
YAMASAKI, Tamio
EINAMA, Takahiro
FUKUMURA, Makiko
HIRATSUKA, Miyuki
KONO, Takako
HAYASHI, Katsumi
ISHIDA, Jiro
UENO, Hideki
TSUDA, Hitoshi
author_sort YAMAGISHI, Yoji
collection PubMed
description BACKGROUND: To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV(max)) at 60 min (SUV(max)1) and SUV(max) at 120 min (SUV(max)2) (ΔSUV(max)%) using dual time point (18)F-fluorodeoxyglucose emission tomography/computed tomography ((18)F-FDG PET/CT) in breast cancer. METHODS: Four hundred and sixty-four patients with primary breast cancer underwent (18)F-FDG PET/CT for preoperative staging. ΔSUV(max)% was defined as (SUV(max)2 − SUV(max)1) / SUV(max)1 × 100. We explored the optimal cutoff value of SUV(max) parameters (SUV(max)1 and ΔSUV(max)%) referring to the event of relapse by using receiver operator characteristic curves. The clinicopathological and prognostic significances of the SUV(max)1 and ΔSUV(max)% were analyzed by Cox’s univariate and multivariate analyses. RESULTS: The optimal cutoff values of SUV(max)1 and ΔSUV(max)% were 3.4 and 12.5, respectively. Relapse-free survival (RFS) curves were significantly different between high and low SUV(max)1 groups (P = 0.0003) and also between high and low ΔSUV(max)% groups (P = 0.0151). In Cox multivariate analysis for RFS, SUV(max)1 was an independent prognostic factor (P = 0.0267) but ΔSUV(max)% was not (P = 0.152). There was a weak correlation between SUV(max)1 and ΔSUV(max)% (P < 0.0001, R(2) = 0.166). On combining SUV(max)1 and ΔSUV(max)%, the subgroups of high SUV(max)1 and high ΔSUV(max)% showed significantly worse prognosis than the other groups in terms of RFS (P = 0.0002). CONCLUSION: Dual time point (18)F-FDG PET/CT evaluation can be a useful method for predicting relapse in patients with breast cancer. The combination of SUV(max)1 and ΔSUV(max)% was able to identify subgroups with worse prognosis more accurately than SUV(max)1 alone.
format Online
Article
Text
id pubmed-6882358
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68823582019-12-03 Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer YAMAGISHI, Yoji KOIWAI, Tomomi YAMASAKI, Tamio EINAMA, Takahiro FUKUMURA, Makiko HIRATSUKA, Miyuki KONO, Takako HAYASHI, Katsumi ISHIDA, Jiro UENO, Hideki TSUDA, Hitoshi BMC Cancer Research Article BACKGROUND: To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV(max)) at 60 min (SUV(max)1) and SUV(max) at 120 min (SUV(max)2) (ΔSUV(max)%) using dual time point (18)F-fluorodeoxyglucose emission tomography/computed tomography ((18)F-FDG PET/CT) in breast cancer. METHODS: Four hundred and sixty-four patients with primary breast cancer underwent (18)F-FDG PET/CT for preoperative staging. ΔSUV(max)% was defined as (SUV(max)2 − SUV(max)1) / SUV(max)1 × 100. We explored the optimal cutoff value of SUV(max) parameters (SUV(max)1 and ΔSUV(max)%) referring to the event of relapse by using receiver operator characteristic curves. The clinicopathological and prognostic significances of the SUV(max)1 and ΔSUV(max)% were analyzed by Cox’s univariate and multivariate analyses. RESULTS: The optimal cutoff values of SUV(max)1 and ΔSUV(max)% were 3.4 and 12.5, respectively. Relapse-free survival (RFS) curves were significantly different between high and low SUV(max)1 groups (P = 0.0003) and also between high and low ΔSUV(max)% groups (P = 0.0151). In Cox multivariate analysis for RFS, SUV(max)1 was an independent prognostic factor (P = 0.0267) but ΔSUV(max)% was not (P = 0.152). There was a weak correlation between SUV(max)1 and ΔSUV(max)% (P < 0.0001, R(2) = 0.166). On combining SUV(max)1 and ΔSUV(max)%, the subgroups of high SUV(max)1 and high ΔSUV(max)% showed significantly worse prognosis than the other groups in terms of RFS (P = 0.0002). CONCLUSION: Dual time point (18)F-FDG PET/CT evaluation can be a useful method for predicting relapse in patients with breast cancer. The combination of SUV(max)1 and ΔSUV(max)% was able to identify subgroups with worse prognosis more accurately than SUV(max)1 alone. BioMed Central 2019-11-27 /pmc/articles/PMC6882358/ /pubmed/31775675 http://dx.doi.org/10.1186/s12885-019-6315-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
YAMAGISHI, Yoji
KOIWAI, Tomomi
YAMASAKI, Tamio
EINAMA, Takahiro
FUKUMURA, Makiko
HIRATSUKA, Miyuki
KONO, Takako
HAYASHI, Katsumi
ISHIDA, Jiro
UENO, Hideki
TSUDA, Hitoshi
Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer
title Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer
title_full Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer
title_fullStr Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer
title_full_unstemmed Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer
title_short Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer
title_sort dual time point (18)f-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)f-fdg pet/ct) in primary breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882358/
https://www.ncbi.nlm.nih.gov/pubmed/31775675
http://dx.doi.org/10.1186/s12885-019-6315-8
work_keys_str_mv AT yamagishiyoji dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT koiwaitomomi dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT yamasakitamio dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT einamatakahiro dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT fukumuramakiko dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT hiratsukamiyuki dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT konotakako dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT hayashikatsumi dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT ishidajiro dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT uenohideki dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer
AT tsudahitoshi dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer